circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
== Trial == At pretrial proceedings in February 1995, Rose pleaded not guilty to ten charges of murder (the murder of Charmaine having been added to the original nine after Fred's suicide, and two counts of rape and indecent assault of young girls having been dropped with a view for later resubmission), though her counsel conceded that circumstantial evidence indicated Rose's willingness to subject young girls to sadistic physical and sexual abuse. Her trial at Winchester Crown Court began on 3 October 1995, with Mr Justice Mantell and a jury. An important early decision by the judge was to admit testimony related to the sexual assault of three women by Fred and Rose, accepting the prosecution's argument that it established a pattern of behaviour repeated in the murders.
Invasive garlic mustard, Alliaria petiolata, and its allelochemical benzyl isothiocyanate were shown to inhibit the growth of three species of EcM fungi grown on white pine seedlings. Changes in EcM communities can have drastic effects on nutrient uptake and community composition of native trees, with far-reaching ecological ramifications.
Marc Laidlaw, the writer for the Half-Life series, later said he had intended Episode Three to end the Half-Life 2 story arc, at which point he would "step away from it and leave it to the next generation". He planned an ending similar to previous games, with Freeman left in "an indeterminate space, on hold ... So one cliffhanger after another ... I expected every installment would end without resolution, for ever and ever."
== History of adipose-derived hormones == It had been shown that adipose tissue secreted some unknown factor that influenced appetite. However, the importance of adipose tissue as an endocrine organ was only fully appreciated in 1995 with the discovery of leptin, the protein product of the Ob gene. Leptin is a strong appetite suppressant that, when depleted, causes early onset severe obesity in humans and in animal models. Low levels of leptin in the blood plasma have been heavily associated with people who have moderate to severe forms of depression. Leptin is known to influence moods and cognition by inducing some structural and functional changes within the hippocampus and prefrontal cortex. Also, leptin has been shown to activate signal transduction pathways associated with dopamine and mTOR, which can increase synaptogenesis. Leptin's role in neuroplasticity is currently still being elucidated, but it has been proven to be active in regions of the brain closely linked to depression. It was found that leptin has antidepressant-like effects similar to that of selective serotonin reuptake inhibitors (SSRIs). The discovery of leptin and its effects on appetite led to hopes of a treatment for obesity and type 2 diabetes, a major disease in the developed world. Unfortunately, clinical studies using leptin as a treatment for obesity in humans failed to show improvement, leading some scientists to conclude that the brain can become resistant to leptin, even at supra-physiological levels (the so-called "ceiling effect"), rendering treatment with leptin ineffective.
Taihō had just launched 42 aircraft as a part of the second raid when Albacore fired the torpedo spread. Of the six torpedoes fired, four veered off-target. Japanese pilot Sakio Komatsu had recently launched and from his aircraft sighted one of the two torpedoes which were heading for Taihō. Komatsu dived into the path of the torpedo which then detonated. The sixth torpedo struck the carrier on her starboard side and ruptured two aviation fuel tanks. The carrier's escorting destroyers made depth charge attacks but caused only minor damage to Albacore. Initially, the damage to Taihō seemed minor; the flooding was quickly contained and the carrier's propulsion and navigation were unaffected. Taihō quickly resumed regular operations, but gasoline vapor from the ruptured fuel tanks began to fill the hangar decks, creating an increasingly dangerous situation on board.
Sources: en.wikipedia.org
=== Contrast agents, bioimaging === Functionalized and surfactant dispersed graphene solutions have been designed as blood pool MRI contrast agents. Further, iodine and manganese incorporating graphene nanoparticles have served as multimodal MRI-computerized tomograph (CT) contrast agents. Graphene micro- and nano-particles have served as contrast agents for photoacoustic and thermoacoustic tomography. Graphene has also been reported to be efficiently taking up cancerous cells thereby enabling the design of drug delivery agents for cancer therapy. Graphene nanoparticles of various morphologies such as graphene nanoribbons, graphene nanoplatelets and graphene nanoonions are non-toxic at low concentrations and do not alter stem cell differentiation suggesting that they may be safe to use for biomedical applications.
==== Public figure ==== Throughout the fifties and sixties, Adorno became a public figure, not simply through his books and essays but also through his appearances in radio and newspapers. In talks, interviews, and round-table discussions broadcast on Hessen Radio, South-West Radio, and Radio Bremen, Adorno discussed topics as diverse as "The Administered World" (September 1950), "What is the Meaning of 'Working Through the Past?'" (February 1960), and "The Teaching Profession and its Taboos" (August 1965). Additionally, he frequently wrote for Frankfurter Allgemeine, Frankfurter Rundschau, and the weekly Die Zeit. At the invitation of Wolfgang Steinecke, Adorno took part in the Darmstadt Summer Courses for New Music in Kranichstein from 1951 to 1958. Yet conflicts between the so-called Darmstadt school, which included composers like Pierre Boulez, Karlheinz Stockhausen, Luigi Nono, Bruno Maderna, Karel Goeyvaerts, Luciano Berio, and Gottfried Michael Koenig, soon arose, receiving explicit expression in Adorno's 1954 lecture, "The Aging of the New Music," where he argued that atonality's freedom was being restricted to serialism in much the same way as it was once restricted by twelve-tone technique. With his friend Eduard Steuermann, Adorno feared that music was being sacrificed to stubborn rationalization. During this time, Adorno not only produced a significant series of notes on Beethoven (which was never completed and only published posthumously) but also published Mahler: A Musical Physiognomy in 1960.
== Compounds == The alkali metals form complete series of compounds with all usually encountered anions, which well illustrate group trends. These compounds can be described as involving the alkali metals losing electrons to acceptor species and forming monopositive ions. This description is most accurate for alkali halides and becomes less and less accurate as cationic and anionic charge increase, and as the anion becomes larger and more polarisable. For instance, ionic bonding gives way to metallic bonding along the series NaCl, Na2O, Na2S, Na3P, Na3As, Na3Sb, Na3Bi, Na.
== Side effects == Side effects of tavapadon may include nausea, headache, dizziness, fatigue or asthenia, dysgeusia, vomiting, dry mouth, and anxiety. Other potential but less common side effects include hypotension, orthostatic hypotension, impulsive control problems, compulsive behaviors, hallucinations, psychotic-like behaviors, and dyskinesia.
Although Ben-Gurion had no legal authority to issue such an order, the order was made legal by the cabinet on 31 May. The same order called for the disbandment of all other Jewish armed forces. The two other Jewish underground organizations, Irgun and Lehi, agreed to join the IDF if they would be able to form independent units and agreed not to make independent arms purchases. This was the background for the Altalena Affair, a confrontation surrounding weapons purchased by the Irgun resulting in a standoff between Irgun members and the newly created IDF. The affair came to an end when Altalena, the ship carrying the arms, was shelled by the IDF. Following the affair, all independent Irgun and Lehi units were either disbanded or merged into the IDF. The Palmach, a leading component of the Haganah, also joined the IDF with provisions. Ben Gurion responded by disbanding its staff in 1949, after which many senior Palmach officers retired, notably its first commander, Yitzhak Sadeh. The new army organized itself when the 1947–48 Civil War in Mandatory Palestine escalated into the 1948 Arab–Israeli War, which saw neighbouring Arab states attack. Twelve infantry and armored brigades formed: Golani, Carmeli, Alexandroni, Kiryati, Givati, Etzioni, the 7th, and 8th armored brigades, Oded, Harel, Yiftach, and Negev. After the war, some of the brigades were converted to reserve units, and others were disbanded. Directorates and corps were created from corps and services in the Haganah. This basic structure in the IDF still exists today.
Sources: en.wikipedia.org
== Environment == Penicillium expansum grows best in wet, cool (<25C) conditions. P. expansum was found to grow most efficiently in a temperature range of 15–27 degrees Celsius (~59–81 °F), with slower growth at lower and higher temperatures. P. expansum grows best in wet conditions; growth rate has been found to be fastest at a relative humidity of 90%. P. expansum infection acidifies host tissues via the secretion of organic acids, and that acidification enhances fungal development, indicating a link between environmental acidity and P. expansum virulence.
=== OXGR1 receptor-independent bioactions === The following actions of α-ketoglutarate have not been evaluated for their dependency on activating OXGR1 and are here assumed to be OXGR1-independent. Futures studies are needed to determine if OXGR1 contributes in whole or part to these actions of α-ketoglutarate.
=== Dextran microsphere applications === Dextran-based microspheres can encapsulate a variety of drugs and provide therapeutic delivery in the treatment of diseases such as cancer, colonic diseases, bone diseases, and cardiovascular diseases.
==== Traumatic calcinosis cutis ==== Traumatic calcinosis cutis is a cutaneous condition characterized by calcification of the skin resulting from the deposition of calcium and phosphorus often resulting from occupational exposure, as in cases reported in oil-field workers and coal miners.
== Dietary sources of energy == The typical human diet consists chiefly of carbohydrates, fats, proteins, water, ethanol, and indigestible components such as bones, seeds, and fibre (mostly cellulose). Carbohydrates, fats, and proteins typically comprise ninety percent of the dry weight of food. Ruminants can extract food energy from the respiration of cellulose because of bacteria in their rumens that decompose it into digestible carbohydrates. Other minor components of the human diet that contribute to its energy content are organic acids such as citric and tartaric, and polyols such as glycerol, xylitol, inositol, and sorbitol. Some nutrients have regulatory roles affected by cell signaling, in addition to providing energy for the body. For example, leucine plays an important role in the regulation of protein metabolism and suppresses an individual's appetite. Small amounts of essential fatty acids, constituents of some fats that cannot be synthesized by the human body, are used (and necessary) for other biochemical processes. The approximate food energy contents of various human diet components, to be used in package labeling according to the EU regulations and UK regulations, are:
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.